Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors

NCT01804530 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

59

Enrollment

INDUSTRY

Sponsor class

Stopped Discontinued

Conditions

Solid Tumor
Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
Tenosynovial Giant Cell Tumor

Interventions

DRUG: PLX7486 TsOH

Sponsor

Plexxikon